Namal Nawana - Smith Nephew Chief Executive Officer, Executive Director

SNN Stock  USD 25.36  0.98  3.72%   

CEO

Mr. Namal Nawana is Chief Executive Officer, Executive Director of the Company. He Joined the Board and was appointed Chief Executive Officer on 7 May 2018. He will stand for election by shareholders at the AGM on 11 April 2019. He is based in Andover, US. Career and experience Prior to Smith Nephew Namal was Chief Executive Officer and a member of the Board of Medical Diagnostics Company Alere Inc, until its 8 billion acquisition by Abbott in 2017. Before joining Alere, Namal spent more than 15 years at Johnson Johnson in progressively senior leadership roles globally including the role of Worldwide President of Johnson Johnsons multibillion dollar spine franchise, DePuy Synthes Spine. In addition to his role as CEO of Smith Nephew, Namal is also a member of the Board of Directors of Hologic, Inc. a Nasdaq listed company and Advamed . Skills and competencies Namal holds an undergraduate degree in Mechanical Engineering and a Masters degree in Medical Science from the University of Adelaide, South Australia, as well as an MBA from Henley Management College. He is a global leader with broad experience in healthcare and medical technology. since 2018.
Age 47
Tenure 6 years
Professional MarksMBA
Phone44 1923 477 100
Webhttps://www.smith-nephew.com

Smith Nephew Management Efficiency

The company has Return on Asset of 0.0427 % which means that on every $100 spent on assets, it made $0.0427 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0502 %, implying that it generated $0.0502 on every 100 dollars invested. Smith Nephew's management efficiency ratios could be used to measure how well Smith Nephew manages its routine affairs as well as how well it operates its assets and liabilities.
The company has 3.08 B in debt with debt to equity (D/E) ratio of 0.54, which is OK given its current industry classification. Smith Nephew SNATS has a current ratio of 1.74, which is typical for the industry and considered as normal. Debt can assist Smith Nephew until it has trouble settling it off, either with new capital or with free cash flow. So, Smith Nephew's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Smith Nephew SNATS sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Smith to invest in growth at high rates of return. When we think about Smith Nephew's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 3 records

CEO Age

Michael RhodesDiscover Financial Services
58
Roger HochschildDiscover Financial Services
59
Eric CFAArtisan Partners Asset
55
Smith Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. Smith Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom. Smith Nephew operates under Medical Devices classification in the United States and is traded on New York Stock Exchange. It employs 18000 people. Smith Nephew SNATS (SNN) is traded on New York Stock Exchange in USA. It is located in Building 5, Watford, United Kingdom, WD18 8YE and employs 18,452 people. Smith Nephew is listed under Health Care Equipment & Supplies category by Fama And French industry classification.

Management Performance

Smith Nephew SNATS Leadership Team

Elected by the shareholders, the Smith Nephew's board of directors comprises two types of representatives: Smith Nephew inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Smith. The board's role is to monitor Smith Nephew's management team and ensure that shareholders' interests are well served. Smith Nephew's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Smith Nephew's outside directors are responsible for providing unbiased perspectives on the board's policies.
Michael Friedman, Non-Executive Independent Director
Helen Barraclough, Company Counsel
Gunthorp Oie, IR Contact Officer
Roland Diggelmann, Chief Executive Officer, Executive Director
Helen Maye, Chief Human Resources Officer
Vinita Bali, Non-Executive Independent Director
Simon Fraser, President - Advanced Wound Management and Global Commercial Operations
Massimiliano Colella, President Europe - Middle East and Africa
Olivier Bohuon, CEO, Director, Chairman of Disclosures Committee, Chairman of Executive Risk Committee and Member of Nomination and Governance Committee
Graham Baker, Chief Financial Officer, Executive Director
Cathy ORourke, Chief Legal and Compliance Officer
Ian Melling, Interim Chief Financial Officer
Roberto Quarta, Non-Executive Independent Chairman of the Board
Joe Metzger, Senior Communications
Rick Medlock, Non-Executive Independent Director
Glenn Warner, President - Advanced Wound Management
Paul Connolly, President Operations
Phil Cowdy, Executive Vice President of Business Development & Corporate Affairs
Angie Risley, Non-Executive Independent Director
Mark Gladwell, President - Global Operations and Global Business Services
John Ma, Non-Executive Independent Director
Vasant Padmanabhan, President - Research & Development
Joseph Papa, Non-Executive Independent Director
Susan Swabey, Company Secretary
Melissa Guerdan, Chief Quality and Regulatory Affairs Officer
Philip Cowdy, Chief Officer
Ian Barlow, Non-Executive Independent Director
Namal Nawana, Chief Executive Officer, Executive Director
Bob White, Non-Executive Independent Director
Diogo MoreiraRato, President - Europe and Canada
Alison Parkes, Chief Officer
Skip Kiil, President - Orthopedics
Erik Engstrom, Non-Executive Independent Director
Deepak Nath, Chief Executive Officer
Matthew Stober, President - Global Operations
Marc Owen, Non-Executive Independent Director
AnneFrancoise Nesmes, Chief Financial Officer, Executive Director
Rodrigo Bianchi, Interim President - Asia Pacific
Brian Larcombe, Senior Independent Non-Executive Director
Elga Lohler, Chief Human Resource Officer
Bradley Cannon, President Orthopaedics
Katarzyna MazurHofsaess, Non-Executive Independent Director
Cyrille Petit, Chief Corporate Development Officer
Julie Brown, CFO, Director and Member of Disclosures Committee
Peter Coenen, President - EMEA Region
Robin Freestone, Senior Non-Executive Independent Director
Virginia Bottomley, Non-Executive Independent Director
Myra Eskes, President - Asia Pacific
Andrew Swift, Vice Relations
Michael Frazzette, President - Advanced Surgical Devices
Ingeborg Oie, VP, Investor Relations
Gordon Howe, President of Global Operations
John Campo, Chief Legal Officer
Brad Cannon, President - Sports Medicine & ENT
Jo Hallas, Non-Executive Director
Catheryn ORourke, Chief Legal and Compliance Officer

Smith Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Smith Nephew a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Smith Nephew in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Smith Nephew's short interest history, or implied volatility extrapolated from Smith Nephew options trading.

Currently Active Assets on Macroaxis

When determining whether Smith Nephew SNATS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Smith Nephew's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Smith Nephew Snats Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Smith Nephew Snats Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Smith Nephew SNATS. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.

Complementary Tools for Smith Stock analysis

When running Smith Nephew's price analysis, check to measure Smith Nephew's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Smith Nephew is operating at the current time. Most of Smith Nephew's value examination focuses on studying past and present price action to predict the probability of Smith Nephew's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Smith Nephew's price. Additionally, you may evaluate how the addition of Smith Nephew to your portfolios can decrease your overall portfolio volatility.
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Is Smith Nephew's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Smith Nephew. If investors know Smith will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Smith Nephew listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Smith Nephew SNATS is measured differently than its book value, which is the value of Smith that is recorded on the company's balance sheet. Investors also form their own opinion of Smith Nephew's value that differs from its market value or its book value, called intrinsic value, which is Smith Nephew's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Smith Nephew's market value can be influenced by many factors that don't directly affect Smith Nephew's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Smith Nephew's value and its price as these two are different measures arrived at by different means. Investors typically determine if Smith Nephew is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Smith Nephew's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.